文献速递复苏、休克与脓毒症创伤与烧伤

创伤出血性休克现代复苏中高血浆红细胞比例:PATCH-trauma试验二次分析

High ratio of plasma to red cells in contemporary resuscitation of haemorrhagic shock after trauma: a secondary analysis of the PATCH-trauma trial.
PubMed 文献 · Scand J Trauma Resusc Emerg Med · 2025-10-02
一句话结论在需大量输血的严重创伤患者中,血浆与红细胞比例高于1:2与28天死亡率降低相关(aOR 0.50,95%CI 0.26-0.96)。

该研究为PATCH-trauma试验的事后二次分析,纳入1310例中372例在医院接受大量输血(前4小时红细胞>4单位)的危重出血创伤患者。高比例血浆输注(每2单位红细胞对应超过1单位血浆)者213例(57.3%),28天死亡116例(31.4%)。校正年龄、神经损伤、损伤严重度、凝血病及血小板、纤维蛋白原浓缩物、冷沉淀和氨甲环酸使用后,高比例血浆与较低死亡率独立相关(aOR 0.50;95%CI 0.26-0.96)。作者结论认为,在大量输血患者中高血浆红细胞比例与死亡率降低相关,提示对危重出血早期提供血浆,并考虑院前血浆。

要点

  • 在需大量输血(前4小时红细胞>4单位)的创伤危重出血患者中,血浆:红细胞高于1:2与28天死亡率降低相关(aOR 0.50;95%CI 0.26-0.96)。
  • 该关联来自校正年龄、神经损伤、损伤严重度、凝血病及血小板、纤维蛋白原浓缩物、冷沉淀和氨甲环酸使用后的多变量logistic回归分析。
  • 入院时初始GCS 3-8分与死亡率升高相关(aOR 6.57;95%CI 2.92-14.80),创伤诱导凝血病亦相关(aOR 5.64;95%CI 2.87-11.1)。
  • 年龄与死亡率升高相关(aOR 1.02;95%CI 1.01-1.03)。
  • 作者结论提示对危重出血早期提供血浆,并考虑院前血浆;此为PATCH-trauma试验的事后二次分析。

适用人群与场景

  • PATCH-trauma试验纳入的危重出血、创伤诱导凝血病高风险的创伤患者。
  • 本次事后分析纳入其中在医院接受大量输血(前4小时红细胞>4单位)的患者372例。

诊断标准与关键阈值

  • 大量输血定义:前4小时输注红细胞>4单位。
  • 高比例血浆:红细胞定义:每2单位红细胞对应超过1单位血浆。

研究设计与关键结果

  • 研究类型:PATCH-trauma随机试验的事后二次分析;共纳入372例接受大量输血的创伤危重出血患者,其中213例(57.3%)接受高比例血浆:红细胞,28天死亡116例(31.4%)。
  • 高比例血浆:红细胞与较低28天死亡率相关(校正比值比aOR 0.50;95%CI 0.26-0.96)。
  • 年龄较大与死亡率升高相关(aOR 1.02;95%CI 1.01-1.03)。
  • 入院时初始GCS 3-8分与死亡率升高相关(aOR 6.57;95%CI 2.92-14.80)。
  • 入院时创伤诱导凝血病与死亡率升高相关(aOR 5.64;95%CI 2.87-11.1)。

证据类型、等级与局限

  • 证据类型:随机对照试验(PATCH-trauma)的事后二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在大量输血管理的危重出血患者中,控制潜在混杂因素后高血浆:红细胞比例与较低死亡率相关;对危重出血早期提供血浆被提示为合理,并考虑院前血浆。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Plasma transfusion is recommended as an initial intervention in most major haemorrhage protocols for trauma resuscitation. With availability of newer blood components, therapeutic agents and investigations for coagulopathy, the marginal benefits of high ratios of plasma to red cells is uncertain. The aim of this study was to report the association of high ratios of plasma: red cells and 28-day mortality in patients with major trauma.

METHODS: The PATCH-Trauma trial enrolled critically bleeding patients at high risk of trauma induced coagulopathy and randomised them to receive prehospital tranexamic acid or placebo. The sub-group of patients who were managed with massive transfusions in hospital (> 4 units of red cells in first 4 h) were included for this post-hoc analysis. Associations of high ratios of plasma (more than 1 unit of plasma for every 2 units of red cells) and 28-day mortality were reported using multivariable logistic regression analysis after adjustment for potential confounders including age, neurological injury, injury severity, coagulopathy and administration of platelets, fibrinogen concentrates, cryoprecipitate and tranexamic acid.

RESULTS: Among 1310 patients enrolled in the PATCH-trauma trial, 372 patients were included for this analysis; 213 (57.3%) received high ratios of plasma: red cells and 116 (31.4%) deaths were recorded at 28 days. High ratios of plasma: red cells were associated with lower mortality (adjusted odds ratio; aOR 0.50; 95%CI: 0.26-0.96). Older age (aOR 1.02; 95%CI: 1.01-1.03), initial Glasgow Coma Scale 3-8 (aOR 6.57; 95%CI: 2.92-14.80) and trauma induced coagulopathy (aOR 5.64; 95%CI: 2.87-11.1) on hospital arrival were associated with higher mortality.

CONCLUSIONS: Among patients with critical bleeding managed with massive transfusions, high ratios of plasma: red cells were associated with lower mortality, after controlling for potential confounders. Ongoing provision of early plasma for management of critical bleeding is indicated with consideration to prehospital plasma.

REGISTRATION: ClinicalTrials.gov number, NCT02187120 (Registered 09 July 2014).

来源:Scand J Trauma Resusc Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Mitra B, Reade MC, Bernard S, et al. High ratio of plasma to red cells in contemporary resuscitation of haemorrhagic shock after trauma: a secondary analysis of the PATCH-trauma trial. Scand J Trauma Resusc Emerg Med. 2025. PMID: 41039456. doi:10.1186/s13049-025-01476-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。